{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T05:13:57Z","timestamp":1739596437060,"version":"3.37.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,14]]},"DOI":"10.7759\/cureus.78981","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T10:27:16Z","timestamp":1739528836000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Outcomes in the First and Subsequent Coronavirus Disease 2019 (COVID-19) Hospital Clusters"],"prefix":"10.7759","author":[{"given":"Yoshinobu","family":"Ohsaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Umekage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiraku","family":"Yanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu F","year":"2020","unstructured":"Wu F, Zhao S, Yu B, et al.. A new coronavirus associated with human respiratory disease in China. Nature. 2020, 579:265-9. 10.1038\/s41586-020-2008-3","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li Q","year":"2020","unstructured":"Li Q, Guan X, Wu P, et al.. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020, 382:1199-207. 10.1056\/NEJMoa2001316","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson S","year":"2020","unstructured":"Richardson S, Hirsch JS, Narasimhan M, et al.. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020, 323:2052-9. 10.1001\/jama.2020.6775","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai Q","year":"2020","unstructured":"Cai Q, Yang M, Liu D, et al.. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020, 6:1192-8. 10.1016\/j.eng.2020.03.007","journal-title":"Engineering (Beijing)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.11.987016","article-title":"The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15","author":"Matsuyama S","year":"2020","unstructured":"Matsuyama S, Kawase M, Nao N, et al.. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020, 10.1101\/2020.03.11.987016","journal-title":"bioRxiv"},{"key":"ref6","unstructured":"A multicenter, open-label, randomized controlled phase II study to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 (RACCO trial). (2020). Accessed. 2025: https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCTs031190269."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac502","article-title":"Early outpatient treatment with remdesivir in patients at high risk for severe COVID-19: a prospective cohort study","volume":"9","author":"Rajme-L\u00f3pez S","year":"2022","unstructured":"Rajme-L\u00f3pez S, Martinez-Guerra BA, Zalapa-Soto J, et al.. Early outpatient treatment with remdesivir in patients at high risk for severe COVID-19: a prospective cohort study. Open Forum Infect Dis. 2022, 9:ofac502. 10.1093\/ofid\/ofac502","journal-title":"Open Forum Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients","volume":"386","author":"Gottlieb RL","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R, et al.. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022, 386:305-15. 10.1056\/NEJMoa2116846","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal A","year":"2022","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al.. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022, 386:509-20. 10.1056\/NEJMoa2116044","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler CC","year":"2023","unstructured":"Butler CC, Hobbs FD, Gbinigie OA, et al.. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023, 401:281-93. 10.1016\/S0140-6736(22)02597-1","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi H","year":"2024","unstructured":"Yotsuyanagi H, Ohmagari N, Doi Y, et al.. Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial. JAMA Netw Open. 2024, 7:e2354991. 10.1001\/jamanetworkopen.2023.54991","journal-title":"JAMA Netw Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.12.e63","article-title":"Loop-mediated isothermal amplification of DNA","volume":"28","author":"Notomi T","year":"2000","unstructured":"Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000, 28:E63. 10.1093\/nar\/28.12.e63","journal-title":"Nucleic Acids Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.35772\/ghmo.2023.01025","article-title":"Difference in clinical courses and causes of COVID-19-related deaths in hospitalized patients infected with omicron and delta variants: a retrospective study in Japan","volume":"4","author":"Sakurai A","year":"2024","unstructured":"Sakurai A, Morioka S, Tsuzuki S, et al.. Difference in clinical courses and causes of COVID-19-related deaths in hospitalized patients infected with omicron and delta variants: a retrospective study in Japan. GHM Open. 2024, 4:23-31. 10.35772\/ghmo.2023.01025","journal-title":"GHM Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2022.01.009","article-title":"Sporadic outbreaks of healthcare-associated COVID-19 infection in a highly-vaccinated inpatient population during a community outbreak of the B.1.617.2 variant: the role of enhanced infection-prevention measures","volume":"50","author":"Wee LE","year":"2022","unstructured":"Wee LE, Conceicao EP, Sim JX, et al.. Sporadic outbreaks of healthcare-associated COVID-19 infection in a highly-vaccinated inpatient population during a community outbreak of the B.1.617.2 variant: the role of enhanced infection-prevention measures. Am J Infect Control. 2022, 50:465-8. 10.1016\/j.ajic.2022.01.009","journal-title":"Am J Infect Control"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-09826-8","article-title":"COVID-19 mortality risk for older men and women","volume":"20","author":"Yanez ND","year":"2020","unstructured":"Yanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health. 2020, 20:1742. 10.1186\/s12889-020-09826-8","journal-title":"BMC Public Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262861","article-title":"Sex-specific difference of in-hospital mortality from COVID-19 in South Korea","volume":"17","author":"Her AY","year":"2022","unstructured":"Her AY, Bhak Y, Jun EJ, et al.. Sex-specific difference of in-hospital mortality from COVID-19 in South Korea. PLoS One. 2022, 17:e0262861. 10.1371\/journal.pone.0262861","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01897-20","article-title":"A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19","volume":"64","author":"Doi Y","year":"2020","unstructured":"Doi Y, Hibino M, Hase R, et al.. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020, 64:e01897-20. 10.1128\/AAC.01897-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","unstructured":"Anti-influenza virus drug \"Avigan\u00ae Tablets\" discontinuation of development for COVID-19. (2022). Accessed. 2025: https:\/\/www.fujifilm.com\/jp\/ja\/news\/list\/8698."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.14033","article-title":"Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic","volume":"27","author":"Kikuchi K","year":"2023","unstructured":"Kikuchi K, Nangaku M, Ryuzaki M, et al.. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic. Ther Apher Dial. 2023, 27:1064-9. 10.1111\/1744-9987.14033","journal-title":"Ther Apher Dial"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-021-00378-0","article-title":"Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study","volume":"7","author":"Kikuchi K","year":"2021","unstructured":"Kikuchi K, Nangaku M, Ryuzaki M, et al.. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study. Ren Replace Ther. 2021, 7:59. 10.1186\/s41100-021-00378-0","journal-title":"Ren Replace Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.61048","article-title":"Real-world efficacy of ensitrelvir in hospitalized patients with COVID-19 in Japan: a retrospective observational study","volume":"16","author":"Yoshida R","year":"2024","unstructured":"Yoshida R, Sasaki T, Ohsaki Y. Real-world efficacy of ensitrelvir in hospitalized patients with COVID-19 in Japan: a retrospective observational study. Cureus. 2024, 16:e61048. 10.7759\/cureus.61048","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/329933-real-world-treatment-outcomes-in-the-first-and-subsequent-coronavirus-disease-2019-covid-19-hospital-clusters","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T10:27:19Z","timestamp":1739528839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/329933-real-world-treatment-outcomes-in-the-first-and-subsequent-coronavirus-disease-2019-covid-19-hospital-clusters"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.78981","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}